Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The primary financial metric disclosed relates to the share buyback transaction executed on July 1, 2011:
- Shares Purchased: 1,250,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,337 pence per share; lowest price paid was 1,327 pence per share.
- Treasury Holdings (Settled): 469,174,284 shares (8.37% of total issued share capital).
- Treasury Holdings (Including Unsettled): 471,324,284 shares (9.18% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,133,885,160 shares.
Material Changes
The filing reports a material change in the Company's capital structure due to the reduction of outstanding shares and the increase in treasury stock. The filing text does not provide comparative financial performance data versus prior periods.
Guidance, Outlook, and Risks
The Company intends to hold the repurchased shares in Treasury. No guidance, outlook, management commentary on operations, risks, contingencies, or unusual items are disclosed in this specific filing.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (469,174,284 settled) against the total issued share capital.
- Confirm the percentage of total voting rights held in Treasury (9.18% including unsettled shares).
- Check the number of shares in issue excluding treasury stock (5,133,885,160) for use in calculating disclosure thresholds under Financial Services Authority rules.
- Note that this filing contains no operational financial results; refer to Form 20-F for comprehensive financial statements.